ERBB3 and brain disorder: In this non-randomized study, stage IV TNBC patients with measurable brain disease receive three triweekly doses of an HER2/HER3-targeted DC vaccine intradermally as well as pembrolizumab in the treatment phase, followed by maintenance doses of triweekly pembrolizumab until disease progression.